

PATENT  
Docket No. 275.00070101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): HSU et al. ) Group Art Unit: 1642  
Serial No.: 10/732,782 ) Examiner: Audrey S. Pham  
Confirmation No.: 6883 )  
Filed: December 10, 2003 )  
)

For: CHEMOPREVENTIVE AND THERAPEUTIC ASPECTS OF POLYPHENOLIC COMPOSITIONS AND ASSAYS

RECEIVED  
CENTRAL FAX CENTER  
APR 25 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. §1.56, and in accordance with C.F.R. §§1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. §609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Since this Information Disclosure Statement is submitted after the receipt of an Office Action in the above-identified patent application, please charge the fee of \$180 under 37 C.F.R. §§1.97(c) and 1.17(p), and any additional fees or credit any overpayment to Deposit Account No. 13-4895.

04/26/2006 JBALINAN 0000063 134895 10732782

01 FC:1806 180.00 DA

Supplemental Information Disclosure Statement  
Serial No. 10/732,782  
Confirmation No. 6883

Page 2 of 2

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.8:
<p>The undersigned hereby certifies that this paper is being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office, addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this <u>25</u> day of <u>April</u>, 2006, at <u>2:20 pm</u> (Central Time).</p> <p><u>Sandy Truehart</u> Name: <u>Sandy Truehart</u></p>

April 25, 2006  
Date

Respectfully submitted  
By  
Mueting, Raasch & Gebhardt, P.A.  
P.O. Box 581415  
Minneapolis, MN 55458-1415  
Phone: (612)305-1220  
Facsimile: (612)305-1228  
**Customer Number 26813**

By: Nancy A. Johnson  
Nancy A. Johnson  
Reg. No. 47,266  
Direct Dial (612)305-4723

<b>INFORMATION DISCLOSURE STATEMENT</b>	Atty. Docket No.: 275.0007 0101	Serial No.: 10/732,782
	Applicant(s): HSU et al.	Confirmation No.: 6883
	Application Filing Date: 12/10/03	Group: 1642
	Information Disclosure Statement mailed:	April 25, 2006

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

**OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)**

Examiner Initial	Copy Enclosed	Document Description
	<input checked="" type="checkbox"/>	Hsu et al., "Green Tea Polyphenol-Induced Epidermal Keratinocyte Differentiation is Associated with Coordinated Expression of p57/KIP2 and Caspase 14," 2005. <i>Journ. Of Pharmacology and Experimental Therapeutics</i> , Vol. 312, No. 3, pages 884-890

<b>EXAMINER</b>	<b>Date Considered</b>
-----------------	------------------------

**\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**